- COVID-19 infection increases risk of a range of neurological diseases,
- Cancer patients eating ice cream can reduce this side effect of chemotherapy
- Gut microbes may become a new therapy for depression and anxiety
- The risk of Alzheimer’s disease increases by 50-80% within a year after COVID-19 infection
- Hong Kong will launch monkeypox vaccination for high-risk groups in October
- Ebola (Sudan strain) outbreak in Uganda
Science: Found a way to restore impaired cognition for Alzheimer’s disease!
Science: Found a way to restore impaired cognition for Alzheimer’s disease!. [Science Sub-Journal] Save brain memory! Scientists have found a way to restore impaired cognition in patients with Alzheimer’s disease!
Recently, researchers from New York University published an essay in the journal Science Signaling, confirming that adding standardized protein synthesis drugs can help restore normal brain activity.
As of 2019, China has more than 10 million patients with Alzheimer’s (hereinafter referred to as AD), which is the country with the largest number of AD patients in the world. The number of patients with Alzheimer’s in China ranks first in the world, accounting for the total population of AD patients This number is still rising with the aging of the population. How to develop effective drugs for Alzheimer’s disease is currently a big problem to understand.
Currently, treatments for Alzheimer’s disease are focused on reducing pain-related phenomena such as amyloid plaque load, neurofibrillary tangles and neuroinflammation.
Recently, researchers from New York University published a paper titled “Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer’s disease” in the journal “Science Signaling”. The study showed that standardized proteins were added Synthetic drugs can help restore normal brain activity.
Mauricio Martins-Oliveira, a postdoctoral fellow at the Center for Neuroscience at New York University, explained: “This work is the first to prove that pharmacological methods can reverse the impaired protein synthesis in the brains of Alzheimer’s patients. This is a feasible and effective method.”
Neuroscientists have identified a potential approach to address the loss of cognitive function caused by Alzheimer’s disease by targeting protein synthesis in mice.
“The synthesis of new proteins in the brain is essential for normal neuronal function, especially for memory consolidation. Our research and previous studies have proved that brain protein synthesis disorders can cause memory defects in Alzheimer’s disease model mice. The brains of patients with Alzheimer’s disease show obvious signs of impaired protein synthesis. Therefore, saving brain protein synthesis may be an effective way to improve memory function in Alzheimer’s disease,” Professor Sergio Ferreira, Institute of Biophysics, Federal University of Brazil Say.
Professor Eric Klann, New York University Neuroscience Center, added: “Given the complexity of Alzheimer’s disease, it has been challenging to identify and target abnormal molecular pathways that effectively improve cognition. The latest findings indicate that protein synthesis in the brain can Restore lost cognitive function. We hope that this work can be a step towards treating this disease.”
The research focused on ISRIB, a synthetic molecule that promotes protein synthesis. ISRIB was developed by Peter Walter of the University of California, San Francisco.
Researchers at NYU and UFRJ are trying to determine whether ISRIB can restore synaptic plasticity (the brain’s ability to change for learning) and memory. Previously, they have shown that the translation initiation ability of the Alzheimer’s brain is impaired, leading the research team to hypothesize that ISRIB can play a role in rebuilding certain cognitive functions.
After the research team determined that in the hippocampus (a brain structure that plays an important role in memory) of Alzheimer’s patients, key components of the protein synthesis mechanism are exhausted, the scientists concluded that protein synthesis may also be impaired .
Then, they performed a series of memory tests (for example, maze navigation) to test whether ISRIB can save the memory of mice with Alzheimer’s disease. It turns out that ISRIB can indeed restore the memory function of these mice and the protein synthesis in the hippocampus.
They also examined whether ISRIB can restore hippocampal function and cognition in mice with complete Alzheimer’s disease, thereby treating the disease at an advanced stage. Similarly, their results showed that ISRIB can restore hippocampal synaptic plasticity and memory function.
As a result, the researchers found that, with the help of synthetic molecules (in this case, ISRIB), restoring protein synthesis can restore impaired cognition in Alzheimer’s patients.
(source:internet, reference only)